The MiSeqDx instrument is the first FDA-cleared in vitro diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDx applications include FDA-cleared and FDA-approved assays for cystic fibrosis testing, colorectal cancer evaluation, and NGS-based assay development.
FDA-cleared next-generation sequencing panels for detection of causative and clinically relevant variants for cystic fibrosis.